Cargando…

Toll-like receptor 2 agonist exacerbates renal injury in diabetic mice

Inflammation is implicated in the pathogenesis of diabetic nephropathy (DN). Toll-like receptor 2 (TLR2) is a ligand-activated membrane-bound receptor, which induces an inflammatory response, thus serving a crucial role in the pathogenesis of DN. The present study aimed to determine whether a TLR2 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Fanglin, Zhang, Ningyu, Li, Zhiming, Deng, Lihua, Zhang, Jianjie, Zhou, Yunfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348689/ https://www.ncbi.nlm.nih.gov/pubmed/28352321 http://dx.doi.org/10.3892/etm.2017.4031

Ejemplares similares

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Toll-like receptor 2 deficiency leads to delayed exacerbation of ischemic injury
por: Bohacek, Ivan, et al.
Publicado: (2012)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
por: Liu, Zhi-Mei, et al.
Publicado: (2022)

Bibliometric analysis of toll-like receptor agonists associated with cancer therapy
por: Li, Wei, et al.
Publicado: (2022)

Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
por: Chakraborty, Samik, et al.
Publicado: (2023)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

Toll-like receptor 4 contributes to acute kidney injury after cardiopulmonary resuscitation in mice
por: Zhang, Qingsong, et al.
Publicado: (2016)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

Toll‐like receptor‐2 exacerbates murine acute viral hepatitis
por: Bleau, Christian, et al.
Publicado: (2016)

Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma
por: Deng, Shuanglin, et al.
Publicado: (2014)

Hypoxia Exacerbates Inflammatory Acute Lung Injury via the Toll-Like Receptor 4 Signaling Pathway
por: Wu, Gang, et al.
Publicado: (2018)

Physical Exercise Exacerbates Acute Kidney Injury Induced by LPS via Toll-Like Receptor 4
por: Húngaro, Talita Guerreiro Rodrigues, et al.
Publicado: (2020)

Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates
por: Chan, Michael, et al.
Publicado: (2009)

Toll-like receptor 2 agonists inhibit human fibrocyte differentiation
por: Maharjan, Anu S, et al.
Publicado: (2010)

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists
por: Macedo, Amanda B., et al.
Publicado: (2019)

The Toll‐like receptor 7 agonist imiquimod increases ethanol self‐administration and induces expression of Toll‐like receptor related genes
por: Lovelock, Dennis F., et al.
Publicado: (2022)

Epithelial immunomodulation by aerosolized Toll-like receptor agonists prevents allergic inflammation in airway mucosa in mice
por: Goldblatt, David L., et al.
Publicado: (2022)

Depletion of Toll-Like Receptor-9 Attenuates Renal Tubulointerstitial Fibrosis After Ischemia-Reperfusion Injury
por: Zheng, Haofeng, et al.
Publicado: (2021)

Role of Toll-like Receptor 3 Variants in Aspirin-Exacerbated Respiratory Disease
por: Palikhe, Nami Shrestha, et al.
Publicado: (2011)

The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice
por: Do, Kim Thi Hoang, et al.
Publicado: (2023)

Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine
por: He, Li-Zhen, et al.
Publicado: (2015)

Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything
por: Hotz, Christian, et al.
Publicado: (2012)

Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
por: Christopher, ME, et al.
Publicado: (2011)

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2012)

Natural toll-like receptor agonists in prophylactic vaccines for dendritic cell activation
por: Peng, Paul, et al.
Publicado: (2015)

The functional and inflammatory response of brain endothelial cells to Toll-Like Receptor agonists
por: Johnson, Rebecca H., et al.
Publicado: (2018)

Toll-Like Receptor Agonists Modulate Wound Regeneration in Airway Epithelial Cells
por: Lewandowska-Polak, Anna, et al.
Publicado: (2018)

Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists
por: Andón, Fernando Torres, et al.
Publicado: (2022)

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
por: Damiano, V, et al.
Publicado: (2013)

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
por: Rosa, Roberta, et al.
Publicado: (2013)

Toll-Like Receptor 4 Reduces Oxidative Injury via Glutathione Activity in Sheep
por: Deng, Shoulong, et al.
Publicado: (2016)

Toll-Like Receptors, Tissue Injury, and Tumourigenesis
por: Ioannou, Savvas, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bjduga7tvufvl3p4erqcgq0p81